Sera Prognostics, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Sera Prognostics, Inc. (Nasdaq: SERA) is a women's health diagnostics company that discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services to assess risks of preterm birth and other pregnancy complications. The company offers the PreTRM test, a non-invasive blood-based biomarker test performed during weeks 18 through 20 of gestation that predicts an asymptomatic singleton pregnancy's individualized risk of spontaneous preterm delivery; the LikeMine platform, which provides personalized pregnancy comparisons and complimentary Complications Summary Reports drawing on data from millions of U.S. pregnancies; and a pipeline of novel blood-based tests targeting conditions including preeclampsia, gestational diabetes mellitus, fetal growth restriction, stillbirth, postpartum depression, time-to-birth prediction, and pregnancy risk prediction panels. Sera Prognostics operates primarily in the United States, with plans to expand commercially in selected geographies and accelerate preparations for entry into the European Union. Founded in 2008 and headquartered at 2749 East Parleys Way, Suite 200, Salt Lake City, Utah, the company utilizes a proprietary proteomics and bioinformatics platform to characterize pregnancy biology and validate predictive protein biomarkers found in maternal blood. In recent developments, Sera Prognostics reported positive full results from its PRIME pivotal study in January 2025, demonstrating a 25% reduction in neonatal morbidity and mortality index and an 18% reduction in neonatal length of hospital stay among the modified intent-to-treat population, with the findings presented at the Society for Maternal-Fetal Medicine 2025 Pregnancy Meeting. The company raised $57.5 million in a public follow-on offering in February 2025, extending its cash runway through 2028 to support expanded U.S. commercial efforts with payers and providers, European Union preparations, and additional studies including a potential U.S. FDA submission for broad PreTRM test approval. Sera Prognostics is also advancing Medicaid pilot expansions and engaging with multiple payers across 13 states to drive PreTRM test adoption and revenue growth.
Company News
1 in 10 U.S. Babies Are Born Too Early. A Leading OB-GYN Says Most Mothers Can Learn Their Risk by Week 21, and Do Something About It.
SERA PROGNOSTICS APPOINTS SCOTT GLEASON CHIEF FINANCIAL OFFICER
Sera Prognostics Q2 Earnings Call Highlights
Sera Prognostics, Inc. (SERA) Q2 2026 Earnings Call Transcript
Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Misses Revenue Estimates
SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026
PRIME SUBGROUP ANALYSIS DEMONSTRATES 22% REDUCTION IN NICU ADMISSIONS IN FIRST-TIME PREGNANCIES USING PreTRM® Test-GUIDED CARE
SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF MARK CAPONE TO ITS BOARD OF DIRECTORS
SERA PROGNOSTICS COLLABORATES ON ARPA-H AWARD TO ADVANCE POINT-OF-CARE DIAGNOSTIC FOR SAFER BIRTH
SERA APPLAUDS ILLINOIS INITIATIVE TO EXPAND MEDICAID COVERAGE FOR PROTEOMIC BLOOD TESTING IN PREGNANCY
All You Need to Know About Sera Prognostics (SERA) Rating Upgrade to Buy
SERA PROGNOSTICS ANNOUNCES BOARD TRANSITION
Sera Prognostics (SERA) Loses 27% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Sera Prognostics, Inc. (SERA) Q1 2026 Earnings Call Transcript
Sera Prognostics, Inc. (SERA) Reports Q1 Loss, Misses Revenue Estimates
SERA PROGNOSTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FIRST QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON MAY 6, 2026
Sera Prognostics (SERA) Upgraded to Buy: What Does It Mean for the Stock?
5 Top-Ranked Stocks With Rising P/E That Investors Can Bet On